Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial).

ESMO Open · 2024 · PMC11549519 · PMID 39461773

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

6 , 17 To assess the impact of crossover on OS benefit in RATIONALE-304, a supportive two-stage method analysis was carried out, which showed a trend toward improvement in OS in the tislelizumab plus chemotherapy arm versus the chemotherapy alone arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.